Global Somatostatin Analogs Market Size, Share, Forecast Report, 2020-2027

Somatostatin Analogs Market is expected to hold a value of about USD 8,640 Million by 2025, and it is projected to grow at a CAGR of 6.8% from 2019 to 2025.
Somatostatin analogs are the drugs that stop the excessive hormone secretion in the body. Neuroendocrine Tumors (NETs) and Acromegaly, a rare hormonal disorder, are the most common indications treated with somatostatin analogs. Some of the other common tumors treated with Somatostatin Analogs are carcinoid tumors, glucagonomas, VIPomas, and GH-secreting tumors. Besides this, Somatostatin Analogs are also used to treat Cushing's syndrome.

Somatostatin analogs have been commercially available for more than three decades. Earlier, the market for somatostatin analogs was dominated by a couple of players including Novartis, and Ipsen. However, the scenario has changed in last few years as the demand for these drugs is increasing. As a result, the number of players is getting involved in the development of generic somatostatin analogs as well as the novel drugs.
Somatostatin Analogs Market Segmentation

By Type

Octreotide: It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. It is the first-ever type of Somatostatin Analogue. It is also the most commonly used somatostatin analog, as it has been commercially available for a long time and has also provided positive results over the years. The top brands of Octreotide are ‘Sandostatin,’ and ‘Sandostatin Lar’ manufactured by Novartis. Some of the generic versions are Otide, Okerson, Octride, and Octronis among others. Octreotide is expected to hold the largest share in the global market during the assessment period.
Lanreotide: It is a long-acting analog manufactured by Ipsen Pharmaceuticals. Lanreotide is marketed as Somatuline. It was approved by FDA in 2017. Lanreotide is commonly used for the treatment of acromegaly and carcinoid tumors.
Pasireotide: It is a long-acting cyclic hexapeptide manufactured initially by Novartis. It is marketed under the brand name Signifor. Pasireotide is expected to be the fastest-growing segment owing to the factors including increasing uptake of the drugs for the treatment of Cushing’s syndrome and other associated medical conditions.
By Treatment

Neuroendocrine Tumor (NET): Neuroendocrine tumors are the largest segment in the global somatostatin analogs market. The major types of neuroendocrine tumors treated with the somatostatin analogs are carcinoid tumors, glucagonomas, VIpomas, and Growth Hormone Secreting Tumors, among others. Somatostatin analogs are used to block the hormone release in these endocrine tumors.
Acromegaly: Acromegaly is caused by the hypersecretion of Growth hormone. Apart from surgery, Somatostatin analogs are used as the primary therapy for the treatment. The treatment goals for acromegaly are to reduce the tumor size and to maintain GH and IGF-1 within normal ranges. Somatostatin analogs inhibit the release of GH from the pituitary gland and help in reducing the growth of the tumors.
Cushing’s Syndrome: Cushing’s syndrome, sometimes also called hypercortisolism is caused when the body excessively produces the hormone cortisol. Moreover, it can occur due to exposure to high levels of the hormone cortisol for a long time and also by the use of oral corticosteroid medication.
Others: The other segment includes chemotherapy, malignant bowel obstruction, and HIV-related diarrhea.

Key Players

• Novartis AG (Switzerland)
• Ipsen Pharma (France)
• Fresenius Kabi (Germany)
• Peptron (South Korea)
• Pfizer Inc. (US)
• Teva Pharmaceuticals Inc. (Israel)